Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine
暂无分享,去创建一个
P. Angus | N. Warner | S. Locarnini | R. Colonno | A. Walsh | L. Discotto | R. Rose | D. Tenney | S. Weinheimer | W. Sievert | S. Levine | K. Pokornowski | M. Plym | Ann W. Walsh | Steven M. Levine | G. Thompson | C. Yu | A. Ayres | A. Bartholomeusz | C. Yu | Cheng F. Yu
[1] Man-Fung Yuen,et al. Viral hepatitis B , 2003, The Lancet.
[2] C. Gibbs,et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.
[3] Michael D. Miller,et al. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.
[4] Angeline Bartholomeusz,et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.
[5] Ching-Lung Lai,et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] H. Van Vlierberghe,et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.
[7] E. Schiff,et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. , 2002 .
[8] R. J. Colonno,et al. Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro , 2002, Antimicrobial Agents and Chemotherapy.
[9] M. Manns,et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.
[10] R. D. de Man,et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. , 2002, Journal of hepatology.
[11] S. Locarnini,et al. Evolving therapies for the treatment of chronic hepatitis B virus infection , 2002, Expert opinion on investigational drugs.
[12] M. Winters,et al. Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication , 2002, Antimicrobial Agents and Chemotherapy.
[13] L. Corey,et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. , 2001, The Journal of infectious diseases.
[14] Tetsuro Kato,et al. Enhanced expression of B7‐1, B7‐2, and intercellular adhesion molecule 1 in sinusoidal endothelial cells by warm ischemia/reperfusion injury in rat liver , 2001, Hepatology.
[15] M. Sherman,et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.
[16] D. Häussinger,et al. Protein kinase C–dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells , 2001, Hepatology.
[17] S. Sarafianos,et al. Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.
[18] T. Cihlar,et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.
[19] William M. Lee,et al. Hepatitis B therapy: The plot thickens , 1999, Hepatology.
[20] W. Mason,et al. Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine , 1999, Antimicrobial Agents and Chemotherapy.
[21] A. Lok,et al. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B , 1999, Journal of viral hepatitis.
[22] R. Hamatake,et al. In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir , 1998, Antimicrobial Agents and Chemotherapy.
[23] K. Walters,et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .
[24] K. Chayama,et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.
[25] J. Cullen,et al. Lamivudine therapy of WHV-infected woodchucks. , 1998, Virology.
[26] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .
[27] R. Hamatake,et al. Generation of Replication-Competent Hepatitis B Virus Nucleocapsids in Insect Cells , 1998, Journal of Virology.
[28] R. Colonno,et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.
[29] P. Angus,et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. , 1997, Journal of hepatology.
[30] S. Goff,et al. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription , 1995, Journal of virology.
[31] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[32] D. Richman,et al. Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.